ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $304 |
| Gross Profit | $0 | $0 | $0 | -$304 |
| % Margin | – | – | – | – |
| R&D Expenses | $28,773 | $30,549 | $24,640 | $31,970 |
| G&A Expenses | $7,898 | $8,515 | $8,078 | $0 |
| SG&A Expenses | $7,898 | $8,515 | $8,078 | $7,296 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36,671 | $39,064 | $32,718 | $39,266 |
| Operating Income | -$36,671 | -$39,064 | -$32,718 | -$39,570 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,084 | $2,709 | $2,697 | $3,263 |
| Pre-Tax Income | -$32,587 | -$36,355 | -$30,021 | -$36,307 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32,587 | -$36,355 | -$30,021 | -$36,307 |
| % Margin | – | – | – | – |
| EPS | -0.33 | -0.47 | -0.42 | -0.51 |
| % Growth | 29.8% | -11.9% | 17.6% | – |
| EPS Diluted | -0.33 | -0.47 | -0.42 | -0.51 |
| Weighted Avg Shares Out | 98,953 | 78,126 | 71,041 | 70,652 |
| Weighted Avg Shares Out Dil | 98,953 | 78,126 | 71,041 | 70,652 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $288 | $310 | $302 | $304 |
| EBITDA | -$32,299 | -$38,754 | -$32,416 | -$36,003 |
| % Margin | – | – | – | – |